Wistuba II - Search Results

1

Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Aramburu A, Zudaire I, Pajares MJ, Agorreta J, Orta A, Lozano MD, Gúrpide A, Gómez-Román J, Martinez-Climent JA, Jassem J, Skrzypski M, Suraokar M, Behrens C, Wistuba II, Pio R, Rubio A, Montuenga LM. Aramburu A, et al. Among authors: wistuba ii. BMC Genomics. 2015 Oct 6;16:752. doi: 10.1186/s12864-015-1935-0. BMC Genomics. 2015. PMID: 26444668 Free PMC article.

2

Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis.

Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Huang J, et al. Ann Diagn Pathol. 2001 Dec;5(6):321-9. doi: 10.1053/adpa.2001.29338. Ann Diagn Pathol. 2001. PMID: 11745069

3

Clonality of combined tumors.

Huang J, Behrens C, Wistuba II, Gazdar AF, Jagirdar J. Huang J, et al. Among authors: wistuba ii. Arch Pathol Lab Med. 2002 Apr;126(4):437-41. doi: 10.5858/2002-126-0437-COCT. Arch Pathol Lab Med. 2002. PMID: 11900568 Free article.

4

Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma.

Wistuba II, Behrens C, Albores-Saavedra J, Delgado R, Lopez F, Gazdar AF. Wistuba II, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3615-9. Clin Cancer Res. 2003. PMID: 14506148

5

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.

Prudkin L, Wistuba II. Prudkin L, et al. Among authors: wistuba ii. Ann Diagn Pathol. 2006 Oct;10(5):306-15. doi: 10.1016/j.anndiagpath.2006.06.011. Ann Diagn Pathol. 2006. PMID: 16979526 Review.

6

Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions.

Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Tang X, et al. Among authors: wistuba ii. Cancer. 2006 Dec 1;107(11):2637-46. doi: 10.1002/cncr.22315. Cancer. 2006. PMID: 17078054 Free article.

7

Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry.

Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Shen J, et al. Among authors: wistuba ii. Cancer Res. 2006 Dec 1;66(23):11194-206. doi: 10.1158/0008-5472.CAN-04-1444. Cancer Res. 2006. PMID: 17145864

8

Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.

Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X. Gu J, et al. Among authors: wistuba ii. Clin Cancer Res. 2006 Dec 15;12(24):7329-38. doi: 10.1158/1078-0432.CCR-06-0894. Clin Cancer Res. 2006. PMID: 17189404

9

Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.

Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Tsao AS, et al. J Thorac Oncol. 2006 Mar;1(3):231-9. doi: 10.1016/s1556-0864(15)31573-2. J Thorac Oncol. 2006. PMID: 17409862 Free article.

10

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. Massarelli E, et al. Among authors: wistuba ii. Clin Cancer Res. 2007 May 15;13(10):2890-6. doi: 10.1158/1078-0432.CCR-06-3043. Clin Cancer Res. 2007. PMID: 17504988

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

728 results

Search Page

Filters